UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

Shares of UCB SA (OTCMKTS:UCBJF) gapped down before the market opened on Thursday . The stock had previously closed at $250.59, but opened at $228.94. UCB shares last traded at $228.94, with a volume of 20 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reiterated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

UCB Price Performance

The business has a 50-day moving average of $265.32 and a 200-day moving average of $286.06. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.